Acurx PharmaceuticalsACXP
13F holders, Q2 2026 (June 30)18holders −3
2new positions
4sold out
$1.55avg. 13F price*
At the end of Q2 2026, 18 institutions reported holding Acurx Pharmaceuticals Inc. (ACXP) in their 13F filings, down 3 from Q1 2026. 2 opened new positions and 4 sold out. The largest holders were Vanguard Capital Management LLC ($48K), Geode Capital Management, LLC ($41K) and Vanguard Fiduciary Trust Co. ($25K).
- Company
- Acurx Pharmaceuticals Inc.
- CUSIP
- 00510M203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $36 |
| Exits | 4 | $78K |
All 13F filers, Q1 2026 → Q2 2026: 4,328 shares bought and 66,533 shares sold, net −62,205 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Vanguard Capital Management LLC | 0.00% | No change | 31,099 | $48K |
| Geode Capital Management, LLC | 0.00% | Add +6.4% | 26,411 | $41K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 16,205 | $25K |
| Jane Street Group, LLC | 0.00% | Reduce -71.2% | 15,727 | $24K |
| Prospect Financial Services LLC | 0.01% | No change | 13,785 | $21K |
| Morgan Stanley | 0.00% | Add +15.4% | 7,500 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +166.2% | 2,744 | $4K |
| Wells Fargo & Company | 0.00% | No change | 2,300 | $4K |
| Westside Investment Management, Inc. | 0.00% | No change | 1,650 | $3K |
| Lanark Financial, Inc. | 0.00% | No change | 1,500 | $2K |
| Barclays PLC | 0.00% | Reduce -26.1% | 281 | $436 |
| Cornerstone Planning Group LLC | 0.00% | No change | 167 | $245 |
| Osaic Holdings, Inc. | 0.00% | No change | 100 | $155 |
| Group One Trading LLC | 0.00% | Reduce -61.2% | 95 | $147 |
| BlackRock, Inc. | 0.00% | No change | 60 | $93 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 23 | $36 |
| SBI Securities Co., Ltd. | 0.00% | No change | 6 | $9 |
| UBS Group AG | 0.00% | Reduce -100.0% | 3 | $5 |
"% of holder's portfolio" is ACXP's weight in each manager's 13F, not the share of Acurx Pharmaceuticals Inc. the manager owns.